469
Views
16
CrossRef citations to date
0
Altmetric
Reviews

Xeroderma Pigmentosa: Three New Cases with an In Depth Review of the Genetic and Clinical Characteristics of the Disease

, , , , , , , , & show all
Pages 120-127 | Received 15 Oct 2014, Accepted 27 Oct 2014, Published online: 02 Dec 2014

REFERENCES

  • Kraemer KH, Myung ML, Scotto J. Xeroderma pigmentosum: Cutaneous, ocular and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241–250.
  • Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis 2011;6:70–75.
  • Kraemer KH, Lutzner MA, Festoff BW, Coon HG. Xeroderma pigmentosum: an inherited disease with sun-sensitivity, multiple cutaneous neoplasms and abnormal DNA repair. Annals Internal Med 1974;80:221–248.
  • Kraemer KH, Patronas NJ, Schiffmann R, et al. Xeroderma pigmentosum, trichothiodystrophy and cockayne syndrome: A complex genotype-phenotype relationship. Neuroscience 2007;145(4): 1388–1396.
  • Bradford PT, Goldstein AM, Tamura D, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterizes the role of DNA repair. J Med Genet 2011;48:168–176.
  • Inui H, Oh K-S, Nadem C, et al. Xeroderma-Pigmentosum-Variant patients from america, europe and asia. J Invest Dermatol 2008;128(8):2055–2068.
  • Kraemer KH, Lee M-M, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer: the xeroderma pigmentdosum paradigm. Arch Dermtatol 1994;130:1018–1021.
  • Taylor AM. Neurodegeneration in xeroderma pigmentosum. Brain 2008;131(8):1967–1968.
  • Brooks PJ. The case for 8,5’-cyclopurine-2’-deoxynucleosides as endogenous DNA lesions that cause neurodegeneration in xeroderma pigmentosum. Neuroscience 2007;145(4):1407–1417.
  • Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000; 16(11–12):1084–1089.
  • Zahid S, Brownell I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J Drugs Dermatol 2008;7(4):405-40-8.
  • Broughton BC, Cordonnier A, Kleijer WJ, et al. Molecular analysis of mutations in DNA polymerase η in xeroderma pigmentosum-variant patients. Proc Natl Acad Sci USA 2002;99(2):815–820.
  • DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012;132:785–796.
  • El Ouazzani Chahdi K, Karim A, Salhi Y, et al. Xeroderma pigmentosum associated with intracerebral tumor: a case report. J Fr Ophthalmol 2010;33(7):495. e1–4.
  • Giglia G, Dumaz N, Drougard C, et al. p53 mutations in skin and internal tumors of xeroderma-pigmentosum patients belonging to the complementation group C. Cancer Res 1998;58(19): 4402–4409.
  • Dabholkar MD, Berger MS, Vionenet JA, et al. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995;55(6):1261–1266.
  • Caggana M, Kilgallen J, Conroy JM, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev 2001;10(4):355–360.
  • Kraemer KH, Lee MM, Scott J. DNA repair protects against cutaneous and internal neoplasia: Evidence from xeroderma pigmentosum. Carcinogenesis 1984;5:511–514.
  • Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 2002;99(2):12985–12990.
  • Goldstein B, Khilnani P, Lapey A, et al. Combined immunodeficiency associated with xeroderma pigmentosum. Pediatric Dermatol 1990;7(2):132–135.
  • Wysenbeek AJ, Weiss H, Duczyminer-Kahana M, et al. Immunologic alterations in xeroderma pigmentosum patients. Cancer 1986;58(2):219–221.
  • Gaspari AA, Fleisher TA, Kraemer KH. Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J Clin Invest 1993;92(3):1135–1142.
  • Mariani E, Facchini A, Honorati MC, et al. Immune defects in families and patients with xeroderma pigmentosum and trichothiodystrophy. Clin Exp Immunol 1992;88(3):376–382.
  • Ramkumar HL, Brooks BP, Cao X, et al. Hema opthalmic manifestations and histopathology of xeroderma pigmentosum-two clinicopathology cases and a review of literature. Surv Opthalmol 2011 Jul-Aug;56(4):348–361.
  • Kleijer WJ, Laugel V, Berneburg M, et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair (Amst). 2008 May 3;7(5):744–750.
  • Kraemer KH, DiGiovanna JJ. Xeroderma Pigmentosum. 2003 Jun 20 [Updated 2014 Feb 13]. Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1397/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.